<DOC>
	<DOCNO>NCT00498043</DOCNO>
	<brief_summary>This Phase II study randomize R-ACVBP R-CHOP induction treatment patient 18 59 DLBCL CD20+ lymphoma 2 3 adverse prognostic factor age-adjusted IPI . The consolidation treatment allocate accord response induction treatment assess PET 2nd 4th induction cycle .</brief_summary>
	<brief_title>A Study Two Associations Rituximab Chemotherapy , With PET-driven Strategy , Lymphoma</brief_title>
	<detailed_description>1 ) Induction Arm A : 4 cycle R-ACVBP , 2 week interval . After 3rd cycle , PET 2+ ( fix ) , collection peripheral blood stem cell progenitor organize time hematological recovery support G-CSF . The consolidation treatment depend result PET evaluation cycle 2 ( PET2 ) cycle 4 ( PET4 ) . - Consolidation 1A ( case PET 2- PET 4 - ) : - High-dose Methotrexate folinic acid rescue ; 2 cycle space 14 day . - Rituximab-Ifosfamide-Etoposide : 4 cycle space 14 day - Cytarabine sub-cutaneous , 4 day ; 2 cycle space 14 day . - Consolidation 2 A ( case PET 2+ PET4 - ) : - 2 cycle high-dose Methotrexate folinic acid rescue - High dose Z- BEAM condition regimen follow autologous transplant . - Salvage ( case PET 4 + ) : The patient treat salvage regimen , biopsy residual mass whenever possible . 2 ) Induction arm B : 4 cycle R-CHOP , 2 week interval . After 3rd cycle , PET 2+ ( fix ) , collection peripheral blood stem cell progenitor organize time hematological recovery support G-CSF . The consolidation treatment depend result PET evaluation cycle 2 ( PET2 ) cycle 4 ( PET4 ) . - Consolidation 1B ( case PET 2- PET 4 - ) : 4 additional cycle R-CHOP , 2-weeks interval - Consolidation 2 B ( case PET 2+ PET 4 - ) : - 2 cycle high-dose Methotrexate folinic acid rescue - High dose Z- BEAM condition regimen follow autologous transplant - Salvage ( case PET 4 + ) : The patient treat salvage regimen , biopsy residual mass whenever possible</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient histologically proven CD20+ diffuse large Bcell lymphoma ( WHO classification ) . Age from18 59 year , eligible transplant . Patient previously treat . Baseline FDGPET Scan ( PET0 ) perform treatment least one hypermetabolic lesion . Index prognostic factor ( IPI ) 2 3 . With minimum life expectancy 3 month . Negative HIV , HBV HCV serologies Â£ 4 week ( except vaccination ) . Having previously sign write informed consent . Any histological type lymphoma . Any history treat nontreated indolent lymphoma . However , patient previously diagnose diffuse large Bcell lymphoma small cell infiltration bone marrow lymph node may include . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Poor renal function ( creatinin level &gt; 150 mmol/l ) , poor hepatic function ( total bilirubin level &gt; 30 mmol/l , transaminases &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5 G/l platelet &lt; 100 G/l , unless relate bone marrow infiltration . Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Any serious active disease ( accord investigator 's decision ) . Treatment investigational drug within 30 day plan first cycle chemotherapy . Pregnant lactate woman woman childbearing potential currently practice adequate method contraception Adult patient tutelage . Impossibility perform baseline PET scan ( PET0 ) randomization treatment begin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>PET</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Rituximab</keyword>
</DOC>